Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Joe Biden warns China over threats to US sovereignty in State of the Union address
    • Fed chair warns of even higher rates if jobs data stays strong
    • Erdoğan declares state of emergency in Turkey after deadly earthquake
    • Iran’s ‘ghost fleet’ switches into Russian oil
    • Chinese spy balloon incursion reveals past US intelligence failings
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Ammunition supply chain crisis: Ukraine war tests Europe in race to rearm
      • Gautam Adani’s ports business to repay $600mn in race to cut debt
      • Jupiter dumps Starling Bank and rules out unlisted stocks
      • Maersk forecasts plunge in profits as container shipping boom ends
      • BP slows oil and gas retreat after record $28bn profit
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Live news updates from February 7: Ukraine’s allies to send up to 178 tanks, Sunak reshuffles cabinet
      • Iran’s ‘ghost fleet’ switches into Russian oil
      • Russia’s budget deficit soars as energy revenues slump by almost half
      • Live news: Zelenskyy thanks Britain on behalf of Ukrainian fighters
      • Jupiter dumps Starling Bank and rules out unlisted stocks
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Lessons from the great reflation
      • Are CEOs with MBAs good for business?
      • Brexit could be reversed — here’s how
      • A Republican-led US would not shrink from the world
      • The revenge of the incumbents
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Barclays chief: the life lessons I have discovered during cancer treatment
      • Management research: why are so few of its ideas taken up?
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • How to ski, shop, sled and sip it in St Moritz
      • American Resistance by David Rothkopf — managing the Trump horror show
      • Inside Vermelho, Christian Louboutin’s new hotel
      • The Rijksmuseum’s Vermeer retrospective is momentous and dizzying
      • Hogwarts Legacy review — 1890s-set prequel is a step forward for Harry Potter
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Jamie Smyth

    US Pharmaceutical Correspondent

    Jamie Smyth is the US pharmaceutical correspondent of the Financial Times. He is based in the New York bureau and covers the pharma and biotech sectors, drug discovery and healthcare issues such as the opioids crisis. He was previously Australia correspondent and Ireland correspondent.

    Before joining the FT Jamie worked as European correspondent for The Irish Times. He has a master’s degree in journalism from Dublin City University and a bachelor’s degree in history from Trinity College Dublin.

    Email Jamie Smyth @JamieSmythF  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Tuesday, 7 February, 2023
      Health sector
      Illumina boosts spending on US lobbying amid opposition to Grail acquisition

      Genome sequencing company paid firms $14.6mn over past two years to try to sway lawmakers

    • Tuesday, 7 February, 2023
      FT News Briefing podcast9 min listen
      The jig is up for the Texas two-step

      UK to design ‘digital pound’ that could fend off a future private tech rival

    • Monday, 6 February, 2023
      News in-depthBankruptcy
      Talc ruling a blow to J&J and the ‘Texas two-step’ bankruptcy jig

      Ruling by US court will make companies think twice about using Chapter 11 schemes to handle lawsuits

    • Tuesday, 31 January, 2023
      Pfizer Inc
      Pfizer forecasts weak sales as demand for Covid products slows

      US drugmaker expects revenues of between $67bn and $71bn this year, down from a record

    • Tuesday, 31 January, 2023
      AbbVie Inc
      Blockbuster AbbVie drug Humira to face competition in US for first time

      Amgen to launch ‘biosimilar’ version of medicine that has generated $200bn in sales since launch

    • Monday, 30 January, 2023
      Johnson & Johnson Co Inc
      J&J blocked from using bankruptcy to resolve talcum powder lawsuits

      Ruling from US appeals court casts doubt on future of contentious ‘Texas two-step’ manoeuvre

    • Sunday, 29 January, 2023
      News in-depthIllumina Inc
      Has Illumina taken the wrong path in its Grail quest?

      DNA sequencing expert’s investors question acquisition of cancer testing group that has also angered EU regulators

    • Sunday, 29 January, 2023
      US police
      Memphis police disband unit connected to death of Tyre Nichols

      Move follows release of video that renewed criticism of US policing tactics

    • Tuesday, 24 January, 2023
      News in-depthDrug prices
      Big pharma groups rejoin battle with governments on drug prices

      Tight budgets and US reforms are ending a truce between the industry and health authorities

    • Sunday, 22 January, 2023
      US opioid epidemic
      US warns overdose crisis will spread overseas without action from China

      White House drugs tsar says Beijing needs to tighten rules on supply of raw materials to make fentanyl

    • Monday, 16 January, 2023
      Bayer AG
      Bayer shifts pharma focus away from ‘innovation unfriendly’ Europe

      German group’s drugs chief warns EU and UK are dissuading investment as company prioritises US and China

    • Saturday, 14 January, 2023
      News in-depthMergers & Acquisitions
      Pharma and biotech seek cure for industry deal slump

      Executives have funding and strategic need for M&A but few are confident to press ahead

    • Tuesday, 10 January, 2023
      Pfizer Inc
      Pfizer gears up to make Covid drug Paxlovid in China

      Demand for antiviral treatment has rocketed after jump in infections following Beijing policy U-turn

    • Monday, 9 January, 2023
      AstraZeneca PLC
      AstraZeneca to buy US biotech CinCor in $1.8bn deal

      Agreement is one of several announced as major healthcare conference begins in San Francisco

    • Friday, 6 January, 2023
      Pharmaceuticals sector
      US approves Alzheimer’s drug that slows rate of cognitive decline

      High price of treatment and restrictions on medicine developed by Eisai and Biogen will limit patient access initially

    • Wednesday, 28 December, 2022
      News in-depthDrugs research
      Race is on to develop new generation of weight-loss drugs

      Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions

    • Tuesday, 20 December, 2022
      Environment
      3M to end ‘forever chemicals’ production as pressure builds

      Conglomerate to phase out Pfas used in products such as mobile phones and non-stick pans

    • Sunday, 18 December, 2022
      Medical science
      US faces lab monkey shortage amid Cambodia smuggling scandal

      Scientists call for more domestic breeding programmes to meet demand for test animals to life sciences sector

    • Thursday, 15 December, 2022
      Drug prices
      Gene therapies may cure disease but can we afford them?

      CSL’s $3.5mn single-dose treatment for haemophilia sparks debate over how to pay for revolutionary drugs

    • Tuesday, 13 December, 2022
      Drugs research
      Moderna’s mRNA cancer vaccine shows promise in early trial

      Study suggests combination with Merck immunotherapy drug reduces risk of death in high-risk patients

    • Monday, 12 December, 2022
      Biotech
      Amgen to buy Horizon Therapeutics for $28.3bn

      California-based biotech wins three-way race to secure new drugs pipeline

    • Wednesday, 7 December, 2022
      Coronavirus pandemic
      China risks ‘wave of infections’ after relaxing zero-Covid policy, warns Fauci

      Joe Biden’s chief medical adviser urges Beijing to approve use of western vaccines

    • Tuesday, 6 December, 2022
      Pharmaceuticals sector
      GSK and Sanofi shares surge after Zantac ruling victory

      US judge dismisses almost 2,500 lawsuits alleging links between heartburn medication and cancer

    • Friday, 2 December, 2022
      Pharmaceuticals sector
      Swedish scientist behind Alzheimer’s drug has big ambitions

      Lars Lannfelt had a key role in developing a drug that has shown some promise in tackling Alzheimer’s

    • Thursday, 1 December, 2022
      Covid-19 vaccines
      US warns Beijing it cannot control Covid-19 without western jabs

      Joe Biden’s coronavirus tsar says Chinese vaccines are ‘not as good’ as alternatives

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In